Exact Sciences (NASDAQ:EXAS) Shares Down 6.4% - What's Next?

Shares of Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) traded down 6.4% during mid-day trading on Thursday . The stock traded as low as $42.89 and last traded at $43.39. 291,914 shares changed hands during trading, a decline of 87% from the average session volume of 2,288,119 shares. The stock had previously closed at $46.35.

Analyst Upgrades and Downgrades

EXAS has been the topic of several recent analyst reports. Piper Sandler reduced their target price on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. BTIG Research upped their price objective on Exact Sciences from $65.00 to $75.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Benchmark reiterated a "buy" rating and issued a $65.00 target price on shares of Exact Sciences in a report on Monday, January 13th. Royal Bank of Canada started coverage on Exact Sciences in a research note on Thursday. They set a "sector perform" rating and a $52.00 price target for the company. Finally, Barclays decreased their target price on Exact Sciences from $70.00 to $65.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Two research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $70.83.

Exact Sciences Stock Performance

The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The stock has a 50-day moving average price of $52.26 and a 200-day moving average price of $59.06. The firm has a market capitalization of $8.03 billion, a PE ratio of -7.75 and a beta of 1.25.

Remove Ads

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. On average, research analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Exact Sciences

Several hedge funds and other institutional investors have recently modified their holdings of EXAS. Price T Rowe Associates Inc. MD increased its holdings in Exact Sciences by 74.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company's stock valued at $323,669,000 after buying an additional 2,462,165 shares during the last quarter. Capital World Investors increased its holdings in shares of Exact Sciences by 10.7% in the 4th quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after acquiring an additional 1,696,321 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of Exact Sciences by 107.7% during the 4th quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company's stock valued at $164,037,000 after acquiring an additional 1,513,873 shares in the last quarter. Groupama Asset Managment bought a new position in Exact Sciences during the third quarter worth $821,000. Finally, Norges Bank acquired a new position in Exact Sciences in the fourth quarter worth $50,625,000. Institutional investors own 88.82% of the company's stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.